AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 58 filers reported holding AKERO THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $98,277,395 | -31.0% | 1,943,009 | -36.3% | 0.22% | -27.8% |
| Q2 2023 | $142,352,067 | +55.7% | 3,048,877 | +27.6% | 0.31% | +50.7% |
| Q1 2023 | $91,437,230 | +25.9% | 2,389,891 | +80.4% | 0.20% | +17.8% |
| Q4 2022 | $72,608,740 | +144.4% | 1,324,977 | +51.9% | 0.17% | +135.1% |
| Q3 2022 | $29,709,000 | +147.9% | 872,500 | +61.6% | 0.07% | +155.2% |
| Q4 2019 | $11,985,000 | +0.3% | 540,000 | +2.9% | 0.03% | 0.0% |
| Q3 2019 | $11,944,000 | +544.9% | 525,000 | +442.8% | 0.03% | +480.0% |
| Q2 2019 | $1,852,000 | – | 96,721 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |